{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:43:13Z","timestamp":1794084193203,"version":"4.8.0"},"reference-count":266,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>Testicular cancer is relatively uncommon and accounts for &lt;1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nerve-sparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with &gt;50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.<\/jats:p>","DOI":"10.6004\/jnccn.2019.0058","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T15:06:32Z","timestamp":1575558392000},"page":"1529-1554","source":"Crossref","is-referenced-by-count":256,"title":["Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"17","author":[{"given":"Timothy","family":"Gilligan","sequence":"first","affiliation":[{"name":"1Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[{"name":"2University of Washington\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"3UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chism","sequence":"additional","affiliation":[{"name":"4Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cost","sequence":"additional","affiliation":[{"name":"5University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ithaar H.","family":"Derweesh","sequence":"additional","affiliation":[{"name":"6UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[{"name":"7University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"8Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Geynisman","sequence":"additional","affiliation":[{"name":"9Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Hancock","sequence":"additional","affiliation":[{"name":"10Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"LaGrange","sequence":"additional","affiliation":[{"name":"11Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis G.","family":"Levine","sequence":"additional","affiliation":[{"name":"12Roswell Park Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Longo","sequence":"additional","affiliation":[{"name":"13Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Lowrance","sequence":"additional","affiliation":[{"name":"14Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"McGregor","sequence":"additional","affiliation":[{"name":"15Dana-Farber\/Brigham and Women's Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monk","sequence":"additional","affiliation":[{"name":"16The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[{"name":"17Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Pierorazio","sequence":"additional","affiliation":[{"name":"18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Rais-Bahrami","sequence":"additional","affiliation":[{"name":"19O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Saylor","sequence":"additional","affiliation":[{"name":"20Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanishka","family":"Sircar","sequence":"additional","affiliation":[{"name":"21The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Smith","sequence":"additional","affiliation":[{"name":"22University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tzou","sequence":"additional","affiliation":[{"name":"23Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vaena","sequence":"additional","affiliation":[{"name":"24St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vaughn","sequence":"additional","affiliation":[{"name":"25Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosj","family":"Yamoah","sequence":"additional","affiliation":[{"name":"26Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Yamzon","sequence":"additional","affiliation":[{"name":"27City of Hope National Medical Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyse","family":"Johnson-Chilla","sequence":"additional","affiliation":[{"name":"28National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keller","sequence":"additional","affiliation":[{"name":"28National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenora A.","family":"Pluchino","sequence":"additional","affiliation":[{"name":"28National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref1891","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/PAS.0000000000001008","article-title":"The significance of spermatic cord involvement by testicular germ cell tumors: should we be staging discontinuous invasion from involved lymphovascular spaces differently from direct extension?","volume":"42","author":"Sanfrancesco","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000078336","article-title":"False-positive human serum chorionic gonadotropin in a patient with a history of germ cell cancer","volume":"66","author":"Trojan","year":"2004","journal-title":"Oncology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/j.1365-2605.2011.01162.x","article-title":"Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour","volume":"34","author":"Turnbull","year":"2011","journal-title":"Int J Androl"},{"key":"ref2501","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.1998.16.4.1287","article-title":"Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study","volume":"16","author":"Nichols","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.eururo.2019.05.031","article-title":"Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer","volume":"76","author":"Calaway","year":"2019","journal-title":"Eur Urol"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/COC.0b013e318277d839","article-title":"Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort","volume":"37","author":"Soper","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1387\/ijdb.130031nv","article-title":"Classification, epidemiology and therapies for testicular germ cell tumours","volume":"57","author":"Vasdev","year":"2013","journal-title":"Int J Dev Biol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejca.2017.07.005","article-title":"No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer","volume":"84","author":"De La Pena","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000331129","article-title":"Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors","volume":"34","author":"Park","year":"2011","journal-title":"Onkologie"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(03)01278-6","article-title":"Part I: testicular cancer--management of early disease","volume":"4","author":"Jones","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"8671832","DOI":"10.1155\/2018\/8671832","article-title":"Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors","volume":"2018","author":"Fung","year":"2018","journal-title":"Adv Urol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.ju.0000053866.68623.da","article-title":"Increasing incidence of testicular cancer worldwide: a review","volume":"170","author":"Huyghe","year":"2003","journal-title":"J Urol"},{"key":"ref2081","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrurol.2016.164","article-title":"Management of stage I testicular germ cell tumours","volume":"13","author":"Chovanec","year":"2016","journal-title":"Nat Rev Urol"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/annonc\/mdv180","article-title":"A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion","volume":"26","author":"Lago-Hernandez","year":"2015","journal-title":"Ann Oncol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.urolonc.2009.01.017","article-title":"Report of the long-term efficacy of two cycles of adjuvant bleomycin\/etoposide\/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group","volume":"29","author":"Bamias","year":"2011","journal-title":"Urol Oncol"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/bjc.1998.587","article-title":"Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group","volume":"78","author":"de Wit","year":"1998","journal-title":"Br J Cancer"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor","volume":"16","author":"Loehrer","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/modpathol.2012.189","article-title":"Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors","volume":"26","author":"Yilmaz","year":"2013","journal-title":"Mod Pathol"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00345-004-0397-9","article-title":"Late relapse of testicular cancer","volume":"22","author":"Lipphardt","year":"2004","journal-title":"World J Urol"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11255-006-0038-x","article-title":"Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer","volume":"38","author":"Mezvrishvili","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/annonc\/mdf058","article-title":"Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer","volume":"13","author":"Strumberg","year":"2002","journal-title":"Ann Oncol"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1634\/theoncologist.2013-0379","article-title":"Postchemotherapy surgery for germ cell tumors\u2013what have we learned in 35 years?","volume":"19","author":"Riggs","year":"2014","journal-title":"Oncologist"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2004.07.178","article-title":"Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref351","first-page":"2575","article-title":"Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres","volume":"12","author":"Ernst","year":"2005","journal-title":"Can J Urol"},{"key":"ref2231","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2001.19.7.2020","article-title":"Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse","volume":"19","author":"Rabbani","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/annonc\/mdf282","article-title":"Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer","volume":"13","author":"Gietema","year":"2002","journal-title":"Ann Oncol"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12032-008-9095-6","article-title":"Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis","volume":"26","author":"Guney","year":"2009","journal-title":"Med Oncol"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2007.11.2078","article-title":"Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection","volume":"25","author":"Carver","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"7272541","DOI":"10.1155\/2018\/7272541","article-title":"Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors","volume":"2018","author":"McHugh","year":"2018","journal-title":"Adv Urol"},{"key":"ref2061","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.urolonc.2009.01.017","article-title":"Report of the long-term efficacy of two cycles of adjuvant bleomycin\/etoposide\/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group","volume":"29","author":"Bamias","year":"2011","journal-title":"Urol Oncol"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/PAS.0000000000000917","article-title":"Do nonseminomatous germ cell tumors of the testis with lymphovascular invasion of the spermatic cord merit staging as pT3?","volume":"41","author":"Gordetsky","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"ref421","first-page":"762","article-title":"Spermatic cord contamination in testicular cancer","volume":"9","author":"Nazeer","year":"1996","journal-title":"Mod Pathol"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdm062","article-title":"Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)","volume":"18","author":"Culine","year":"2007","journal-title":"Ann Oncol"},{"key":"ref1271","first-page":"36","article-title":"Phase II study of daily oral etoposide in refractory germ cell tumors","volume":"17","author":"Miller","year":"1990","journal-title":"Semin Oncol"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0022-5347(17)34874-7","article-title":"Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis","volume":"151","author":"Horwich","year":"1994","journal-title":"J Urol"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","article-title":"Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database","volume":"29","author":"Lorch","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref2361","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(03)01279-8","article-title":"Part II: testicular cancer--management of advanced disease","volume":"4","author":"Jones","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.eururo.2010.12.010","article-title":"Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital\u2019s experience","volume":"59","author":"Sturgeon","year":"2011","journal-title":"Eur Urol"},{"key":"ref2671","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.eururo.2012.08.014","article-title":"Contemporary management of postchemotherapy testis cancer","volume":"62","author":"Daneshmand","year":"2012","journal-title":"Eur Urol"},{"key":"ref2541","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00345-004-0397-9","article-title":"Late relapse of testicular cancer","volume":"22","author":"Lipphardt","year":"2004","journal-title":"World J Urol"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2000.18.2.358","article-title":"Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer","volume":"18","author":"Sweeney","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(03)01279-8","article-title":"Part II: testicular cancer--management of advanced disease","volume":"4","author":"Jones","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2003.01.094","article-title":"Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review","volume":"21","author":"Vergouwe","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1464-410X.2009.08858.x","article-title":"Surveillance in stage I nonseminomatous germ cell tumours of the testis","volume":"104","author":"Zuniga","year":"2009","journal-title":"BJU Int"},{"key":"ref2681","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1008388328809","article-title":"First-line high-dose chemotherapy +\/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases","volume":"11","author":"Kollmannsberger","year":"2000","journal-title":"Ann Oncol"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdw605","article-title":"Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours","volume":"28","author":"Heidenreich","year":"2017","journal-title":"Ann Oncol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2008-0159","article-title":"False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literature","volume":"13","author":"Ballieux","year":"2008","journal-title":"Oncologist"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/era.10.219","article-title":"Serum tumor markers and their utilization in the management of germ-cell tumors in adult males","volume":"11","author":"Salem","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5152\/tud.2013.062","article-title":"Bilateral testicular germ cell tumors","volume":"39","author":"Sar\u0131c\u0131","year":"2013","journal-title":"Turk J Urol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.eururo.2010.12.010","article-title":"Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital\u2019s experience","volume":"59","author":"Sturgeon","year":"2011","journal-title":"Eur Urol"},{"key":"ref2561","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","article-title":"Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database","volume":"29","author":"Lorch","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref2691","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"ref2521","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-5347(05)67365-X","article-title":"Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers","volume":"164","author":"Albers","year":"2000","journal-title":"J Urol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00432-014-1760-x","article-title":"Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor","volume":"141","author":"Kurobe","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.urology.2011.02.002","article-title":"Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy","volume":"78","author":"Kundu","year":"2011","journal-title":"Urology"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2004.07.178","article-title":"Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor","volume":"16","author":"Loehrer","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref2631","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/bjc.1998.587","article-title":"Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group","volume":"78","author":"de Wit","year":"1998","journal-title":"Br J Cancer"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.ju.0000165163.03805.37","article-title":"Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and\/or lymphovascular invasion","volume":"174","author":"Stephenson","year":"2005","journal-title":"J Urol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/cncr.11950","article-title":"Fertility after testicular cancer treatments: results of a large multicenter study","volume":"100","author":"Huyghe","year":"2004","journal-title":"Cancer"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.juro.2006.06.012","article-title":"Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?","volume":"176","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"ref2441","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.eururo.2012.08.014","article-title":"Contemporary management of postchemotherapy testis cancer","volume":"62","author":"Daneshmand","year":"2012","journal-title":"Eur Urol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2011.37.4025","article-title":"Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer","volume":"30","author":"Sprauten","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2006.09.3831","article-title":"18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group","volume":"25","author":"Huddart","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref2191","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/aja.2013.16","article-title":"Clinical outcomes in patients with stage I non-seminomatous germ cell cancer","volume":"15","author":"Lv","year":"2013","journal-title":"Asian J Androl"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2017.77.0735","article-title":"Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study","volume":"36","author":"Kerns","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2003.07.169","article-title":"Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial","volume":"21","author":"Albers","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/COC.0b013e318277d839","article-title":"Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort","volume":"37","author":"Soper","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/PAS.0000000000000917","article-title":"Do nonseminomatous germ cell tumors of the testis with lymphovascular invasion of the spermatic cord merit staging as pT3?","volume":"41","author":"Gordetsky","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2007.11.2078","article-title":"Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection","volume":"25","author":"Carver","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1373\/clinchem.2017.275263","article-title":"Human chorionic gonadotropin assays for testicular tumors: closing the gap between clinical and laboratory practice","volume":"64","author":"Ferraro","year":"2018","journal-title":"Clin Chem"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"ref2531","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1200\/JCO.2003.03.019","article-title":"Update on late relapse of germ cell tumor: a clinical and molecular analysis","volume":"21","author":"George","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12894-015-0010-0","article-title":"Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction","volume":"15","author":"Dieckmann","year":"2015","journal-title":"BMC Urol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.ju.0000165163.03805.37","article-title":"Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and\/or lymphovascular invasion","volume":"174","author":"Stephenson","year":"2005","journal-title":"J Urol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"8781698","DOI":"10.1155\/2018\/8781698","article-title":"Adjuvant therapy for stage IB germ cell tumors: one versus two cycles of BEP","volume":"2018","author":"Huddart","year":"2018","journal-title":"Adv Urol"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.ju.0000053866.68623.da","article-title":"Increasing incidence of testicular cancer worldwide: a review","volume":"170","author":"Huyghe","year":"2003","journal-title":"J Urol"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-5347(05)67365-X","article-title":"Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers","volume":"164","author":"Albers","year":"2000","journal-title":"J Urol"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/j.1365-2605.2011.01162.x","article-title":"Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour","volume":"34","author":"Turnbull","year":"2011","journal-title":"Int J Androl"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1746-1596-8-57","article-title":"Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy","volume":"8","author":"Kobayashi","year":"2013","journal-title":"Diagn Pathol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/aja.2013.16","article-title":"Clinical outcomes in patients with stage I non-seminomatous germ cell cancer","volume":"15","author":"Lv","year":"2013","journal-title":"Asian J Androl"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","article-title":"Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program","volume":"27","author":"Tandstad","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2004.03.022","article-title":"Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and\/or vascular invasion","volume":"46","author":"Chevreau","year":"2004","journal-title":"Eur Urol"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1464-410X.2009.08860.x","article-title":"Surgical management of low-stage nonseminomatous germ cell testicular cancer","volume":"104","author":"Stephenson","year":"2009","journal-title":"BJU Int"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.urology.2003.10.023","article-title":"Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy","volume":"63","author":"Oliver","year":"2004","journal-title":"Urology"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/annonc\/mds579","article-title":"Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer","volume":"24","author":"Beyer","year":"2013","journal-title":"Ann Oncol"},{"key":"ref2551","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1159\/000448868","article-title":"Ongoing clinical trials in testicular cancer: the TIGER trial","volume":"39","author":"Oing","year":"2016","journal-title":"Oncol Res Treat"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/jnci\/dji185","article-title":"Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men","volume":"97","author":"Foss\u00e5","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref111","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.0.CO;2-A","article-title":"Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis","volume":"83","author":"Heidenreich","year":"1998","journal-title":"Cancer"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ejca.2005.08.043","article-title":"Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis","volume":"42","author":"van Dijk","year":"2006","journal-title":"Eur J Cancer"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2005.07.132","article-title":"Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome","volume":"23","author":"Stephenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0022-5347(05)67807-X","article-title":"Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors","volume":"163","author":"Morris","year":"2000","journal-title":"J Urol"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/0284186X.2018.1433323","article-title":"Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study","volume":"57","author":"Haugnes","year":"2018","journal-title":"Acta Oncol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.juro.2011.07.075","article-title":"Testicular prostheses for testis cancer survivors: patient perspectives and predictors of long-term satisfaction","volume":"186","author":"Yossepowitch","year":"2011","journal-title":"J Urol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1442-2042.2002.00520.x","article-title":"Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy","volume":"9","author":"Nonomura","year":"2002","journal-title":"Int J Urol"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/j.clgc.2017.10.008","article-title":"Long-term survival of good-risk germ cell tumor patients after postchemotherapy retroperitoneal lymph node dissection: a comparison of BEP x 3 vs EP x 4 and treating institution","volume":"16","author":"Cary","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/annonc\/mdh301","article-title":"European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)","volume":"15","author":"Schmoll","year":"2004","journal-title":"Ann Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1159\/000020197","article-title":"RPLND or primary chemotherapy in clinical stage IIA\/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment","volume":"37","author":"Weissbach","year":"2000","journal-title":"Eur Urol"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","article-title":"Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"22","author":"Kollmannsberger","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/0970-1591.60450","article-title":"Prognostic features and markers for testicular cancer management","volume":"26","author":"Leman","year":"2010","journal-title":"Indian J Urol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2006.09.3831","article-title":"18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group","volume":"25","author":"Huddart","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1561","first-page":"1425","article-title":"Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases","volume":"5","author":"Nazeer","year":"1998","journal-title":"Oncol Rep"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bju.12920","article-title":"Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy","volume":"117","author":"Robinson","year":"2016","journal-title":"BJU Int"},{"key":"ref2101","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bju.14771","article-title":"Global, regional and national burden of testicular cancer, 1990-2016: results from the Global Burden of Disease Study 2016","volume":"124","author":"Pishgar","year":"2019","journal-title":"BJU Int"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1677\/ERC-09-0254","article-title":"Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype","volume":"17","author":"Greene","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.21185","article-title":"Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer","volume":"104","author":"Saito","year":"2005","journal-title":"Cancer"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.2009.26.4481","article-title":"American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors","volume":"28","author":"Gilligan","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/0970-1591.60450","article-title":"Prognostic features and markers for testicular cancer management","volume":"26","author":"Leman","year":"2010","journal-title":"Indian J Urol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00005392-200102000-00022","article-title":"Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer","volume":"165","author":"B\u00f6hlen","year":"2001","journal-title":"J Urol"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"8781698","DOI":"10.1155\/2018\/8781698","article-title":"Adjuvant therapy for stage IB germ cell tumors: one versus two cycles of BEP","volume":"2018","author":"Huddart","year":"2018","journal-title":"Adv Urol"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/his.13667","article-title":"Pathological risk factors for higher clinical stage in testicular seminomas","volume":"73","author":"Trevino","year":"2018","journal-title":"Histopathology"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2017.09.029","article-title":"Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases","volume":"87","author":"Loriot","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.eururo.2019.05.031","article-title":"Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer","volume":"76","author":"Calaway","year":"2019","journal-title":"Eur Urol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2004.03.022","article-title":"Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and\/or vascular invasion","volume":"46","author":"Chevreau","year":"2004","journal-title":"Eur Urol"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1158\/1055-9965.EPI-10-0031","article-title":"International trends in the incidence of testicular cancer, 1973-2002","volume":"19","author":"Chia","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12032-008-9095-6","article-title":"Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis","volume":"26","author":"Guney","year":"2009","journal-title":"Med Oncol"},{"key":"ref2571","doi-asserted-by":"crossref","first-page":"7272541","DOI":"10.1155\/2018\/7272541","article-title":"Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors","volume":"2018","author":"McHugh","year":"2018","journal-title":"Adv Urol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/annonc\/mdv180","article-title":"A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion","volume":"26","author":"Lago-Hernandez","year":"2015","journal-title":"Ann Oncol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/0284186X.2018.1433323","article-title":"Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study","volume":"57","author":"Haugnes","year":"2018","journal-title":"Acta Oncol"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bju.12920","article-title":"Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy","volume":"117","author":"Robinson","year":"2016","journal-title":"BJU Int"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1078-0432.CCR-15-1186","article-title":"Defining a new prognostic index for stage I nonseminomatous germ cell tumors using CXCL12 expression and proportion of embryonal carcinoma","volume":"22","author":"Gilbert","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000351812","article-title":"Management of brain metastases from germ cell tumors: a single center experience","volume":"85","author":"Boyle","year":"2013","journal-title":"Oncology"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0022-5347(17)34874-7","article-title":"Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis","volume":"151","author":"Horwich","year":"1994","journal-title":"J Urol"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.11229","article-title":"Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients","volume":"97","author":"Ragni","year":"2003","journal-title":"Cancer"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"ref2301","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00005392-199501000-00030","article-title":"The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989)","volume":"153","author":"Donohue","year":"1995","journal-title":"J Urol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0959-8049(00)00442-1","article-title":"Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse","volume":"37","author":"Alexandre","year":"2001","journal-title":"Eur J Cancer"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/jnci\/dji339","article-title":"Paternity following treatment for testicular cancer","volume":"97","author":"Bryd\u00f8y","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2015.62.7000","article-title":"Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the global germ cell cancer group","volume":"34","author":"Feldman","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1200\/JCO.2003.03.019","article-title":"Update on late relapse of germ cell tumor: a clinical and molecular analysis","volume":"21","author":"George","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdm526","article-title":"Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group","volume":"19","author":"Bokemeyer","year":"2008","journal-title":"Ann Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2000.18.2.358","article-title":"Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer","volume":"18","author":"Sweeney","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2006.07.7271","article-title":"Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"25","author":"Einhorn","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bju.14771","article-title":"Global, regional and national burden of testicular cancer, 1990-2016: results from the Global Burden of Disease Study 2016","volume":"124","author":"Pishgar","year":"2019","journal-title":"BJU Int"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.21185","article-title":"Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer","volume":"104","author":"Saito","year":"2005","journal-title":"Cancer"},{"key":"ref2261","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0959-8049(99)00316-0","article-title":"Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indiana University experience","volume":"36","author":"Behnia","year":"2000","journal-title":"Eur J Cancer"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ejca.2005.08.043","article-title":"Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis","volume":"42","author":"van Dijk","year":"2006","journal-title":"Eur J Cancer"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"8671832","DOI":"10.1155\/2018\/8671832","article-title":"Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors","volume":"2018","author":"Fung","year":"2018","journal-title":"Adv Urol"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2008-0159","article-title":"False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literature","volume":"13","author":"Ballieux","year":"2008","journal-title":"Oncologist"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12894-015-0010-0","article-title":"Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction","volume":"15","author":"Dieckmann","year":"2015","journal-title":"BMC Urol"},{"key":"ref2711","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/annonc\/mdh301","article-title":"European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)","volume":"15","author":"Schmoll","year":"2004","journal-title":"Ann Oncol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/annonc\/mdu375","article-title":"One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group","volume":"25","author":"Tandstad","year":"2014","journal-title":"Ann Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mds460","article-title":"Testicular cancer in Europe and the USA: survival still rising among older patients","volume":"24","author":"Verhoeven","year":"2013","journal-title":"Ann Oncol"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5489\/cuaj.3024","article-title":"Do retroperitoneal extragonadal germ cell tumours exist?","volume":"9","author":"Punjani","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"ref31","first-page":"417","article-title":"Global incidence and outcome of testicular cancer","volume":"5","author":"Shanmugalingam","year":"2013","journal-title":"Clin Epidemiol"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000078336","article-title":"False-positive human serum chorionic gonadotropin in a patient with a history of germ cell cancer","volume":"66","author":"Trojan","year":"2004","journal-title":"Oncology"},{"key":"ref2591","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.eururo.2006.05.011","article-title":"Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor","volume":"50","author":"De Giorgi","year":"2006","journal-title":"Eur Urol"},{"key":"ref2471","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdw605","article-title":"Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours","volume":"28","author":"Heidenreich","year":"2017","journal-title":"Ann Oncol"},{"key":"ref2511","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1158\/1055-9965.EPI-10-0031","article-title":"International trends in the incidence of testicular cancer, 1973-2002","volume":"19","author":"Chia","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1148\/rg.275065172","article-title":"US MR imaging correlation in pathologic conditions of the scrotum","volume":"27","author":"Kim","year":"2007","journal-title":"Radiographics"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/PAS.0000000000001008","article-title":"The significance of spermatic cord involvement by testicular germ cell tumors: should we be staging discontinuous invasion from involved lymphovascular spaces differently from direct extension?","volume":"42","author":"Sanfrancesco","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"ref2481","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000331129","article-title":"Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors","volume":"34","author":"Park","year":"2011","journal-title":"Onkologie"},{"key":"ref1411","first-page":"417","article-title":"Global incidence and outcome of testicular cancer","volume":"5","author":"Shanmugalingam","year":"2013","journal-title":"Clin Epidemiol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann Oncol"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/modpathol.2012.189","article-title":"Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors","volume":"26","author":"Yilmaz","year":"2013","journal-title":"Mod Pathol"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1464-410X.2009.08860.x","article-title":"Surgical management of low-stage nonseminomatous germ cell testicular cancer","volume":"104","author":"Stephenson","year":"2009","journal-title":"BJU Int"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/j.clgc.2017.10.008","article-title":"Long-term survival of good-risk germ cell tumor patients after postchemotherapy retroperitoneal lymph node dissection: a comparison of BEP x 3 vs EP x 4 and treating institution","volume":"16","author":"Cary","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5152\/tud.2013.062","article-title":"Bilateral testicular germ cell tumors","volume":"39","author":"Sar\u0131c\u0131","year":"2013","journal-title":"Turk J Urol"},{"key":"ref2351","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1200\/JCO.2005.03.6616","article-title":"Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.clon.2019.04.008","article-title":"Neurotoxicity among survivors of testicular cancer: a population-based study","volume":"31","author":"Raphael","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref181","first-page":"1425","article-title":"Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases","volume":"5","author":"Nazeer","year":"1998","journal-title":"Oncol Rep"},{"key":"ref2621","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/COC.0b013e31829e19e0","article-title":"Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"38","author":"Mulherin","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1078-0432.CCR-15-1186","article-title":"Defining a new prognostic index for stage I nonseminomatous germ cell tumors using CXCL12 expression and proportion of embryonal carcinoma","volume":"22","author":"Gilbert","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref2601","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2006.07.7271","article-title":"Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"25","author":"Einhorn","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref2641","doi-asserted-by":"crossref","first-page":"167.e21","DOI":"10.1016\/j.urolonc.2015.11.007","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care\u2013registry data from an outcomes research project of the German Testicular Cancer Study Group","volume":"34","author":"Seidel","year":"2016","journal-title":"Urol Oncol"},{"key":"ref2701","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2015.62.7000","article-title":"Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the global germ cell cancer group","volume":"34","author":"Feldman","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/0284186X.2018.1449249","article-title":"Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life","volume":"57","author":"Schmidt","year":"2018","journal-title":"Acta Oncol"},{"key":"ref2651","first-page":"36","article-title":"Phase II study of daily oral etoposide in refractory germ cell tumors","volume":"17","author":"Miller","year":"1990","journal-title":"Semin Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/cncr.11950","article-title":"Fertility after testicular cancer treatments: results of a large multicenter study","volume":"100","author":"Huyghe","year":"2004","journal-title":"Cancer"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrurol.2016.164","article-title":"Management of stage I testicular germ cell tumours","volume":"13","author":"Chovanec","year":"2016","journal-title":"Nat Rev Urol"},{"key":"ref2741","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2017.09.029","article-title":"Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases","volume":"87","author":"Loriot","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/01.ju.0000087822.71739.9a","article-title":"Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors","volume":"170","author":"Sheinfeld","year":"2003","journal-title":"J Urol"},{"key":"ref1731","first-page":"2575","article-title":"Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres","volume":"12","author":"Ernst","year":"2005","journal-title":"Can J Urol"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1746-1596-8-57","article-title":"Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy","volume":"8","author":"Kobayashi","year":"2013","journal-title":"Diagn Pathol"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2003.01.094","article-title":"Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review","volume":"21","author":"Vergouwe","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(03)01278-6","article-title":"Part I: testicular cancer--management of early disease","volume":"4","author":"Jones","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann Oncol"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.juro.2011.07.075","article-title":"Testicular prostheses for testis cancer survivors: patient perspectives and predictors of long-term satisfaction","volume":"186","author":"Yossepowitch","year":"2011","journal-title":"J Urol"},{"key":"ref1801","first-page":"762","article-title":"Spermatic cord contamination in testicular cancer","volume":"9","author":"Nazeer","year":"1996","journal-title":"Mod Pathol"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.1998.16.4.1287","article-title":"Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study","volume":"16","author":"Nichols","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/jnci\/dji185","article-title":"Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men","volume":"97","author":"Foss\u00e5","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0959-8049(99)00316-0","article-title":"Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indiana University experience","volume":"36","author":"Behnia","year":"2000","journal-title":"Eur J Cancer"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1373\/clinchem.2017.275263","article-title":"Human chorionic gonadotropin assays for testicular tumors: closing the gap between clinical and laboratory practice","volume":"64","author":"Ferraro","year":"2018","journal-title":"Clin Chem"},{"key":"ref2721","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/annonc\/mds579","article-title":"Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer","volume":"24","author":"Beyer","year":"2013","journal-title":"Ann Oncol"},{"key":"ref2581","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdm526","article-title":"Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group","volume":"19","author":"Bokemeyer","year":"2008","journal-title":"Ann Oncol"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejca.2017.07.005","article-title":"No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer","volume":"84","author":"De La Pena","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1373\/clinchem.2007.088518","article-title":"Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma","volume":"53","author":"Lempi\u00e4inen","year":"2007","journal-title":"Clin Chem"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/his.13667","article-title":"Pathological risk factors for higher clinical stage in testicular seminomas","volume":"73","author":"Trevino","year":"2018","journal-title":"Histopathology"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2013.53.5831","article-title":"Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort","volume":"32","author":"Daugaard","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"167.e21","DOI":"10.1016\/j.urolonc.2015.11.007","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care\u2013registry data from an outcomes research project of the German Testicular Cancer Study Group","volume":"34","author":"Seidel","year":"2016","journal-title":"Urol Oncol"},{"key":"ref1281","article-title":"Administration FDA grants accelerated approval to pembrolizumab for first tissue site agnostic indication Available at https www fda gov drugs informationondrugs approveddrugs ucm htm Accessed","year":"2017","journal-title":"Food Drug October"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1200\/JCO.2005.03.6616","article-title":"Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/jnci\/dji339","article-title":"Paternity following treatment for testicular cancer","volume":"97","author":"Bryd\u00f8y","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref2181","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.clon.2019.04.008","article-title":"Neurotoxicity among survivors of testicular cancer: a population-based study","volume":"31","author":"Raphael","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00432-014-1760-x","article-title":"Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor","volume":"141","author":"Kurobe","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/annonc\/mdf282","article-title":"Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer","volume":"13","author":"Gietema","year":"2002","journal-title":"Ann Oncol"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1200\/JCO.2007.12.0808","article-title":"Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/annonc\/mdf058","article-title":"Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer","volume":"13","author":"Strumberg","year":"2002","journal-title":"Ann Oncol"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","article-title":"Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program","volume":"27","author":"Tandstad","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2611","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","article-title":"Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"22","author":"Kollmannsberger","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1373\/clinchem.2007.088518","article-title":"Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma","volume":"53","author":"Lempi\u00e4inen","year":"2007","journal-title":"Clin Chem"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1464-410X.2009.08858.x","article-title":"Surveillance in stage I nonseminomatous germ cell tumours of the testis","volume":"104","author":"Zuniga","year":"2009","journal-title":"BJU Int"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2011.37.4025","article-title":"Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer","volume":"30","author":"Sprauten","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0022-5347(05)67807-X","article-title":"Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors","volume":"163","author":"Morris","year":"2000","journal-title":"J Urol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.urology.2003.10.023","article-title":"Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy","volume":"63","author":"Oliver","year":"2004","journal-title":"Urology"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/annonc\/mdn170","article-title":"[18F]-FDG-PET in clinical stage I\/II non-seminomatous germ cell tumours: results of the German multicentre trial","volume":"19","author":"de Wit","year":"2008","journal-title":"Ann Oncol"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1159\/000020197","article-title":"RPLND or primary chemotherapy in clinical stage IIA\/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment","volume":"37","author":"Weissbach","year":"2000","journal-title":"Eur Urol"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.2009.26.4481","article-title":"American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors","volume":"28","author":"Gilligan","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1200\/JCO.2007.12.0808","article-title":"Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1634\/theoncologist.2013-0379","article-title":"Postchemotherapy surgery for germ cell tumors\u2013what have we learned in 35 years?","volume":"19","author":"Riggs","year":"2014","journal-title":"Oncologist"},{"key":"ref2201","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11255-006-0038-x","article-title":"Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer","volume":"38","author":"Mezvrishvili","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2009.23.0755","article-title":"Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery","volume":"28","author":"Kollmannsberger","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1159\/000448868","article-title":"Ongoing clinical trials in testicular cancer: the TIGER trial","volume":"39","author":"Oing","year":"2016","journal-title":"Oncol Res Treat"},{"key":"ref2661","article-title":"Administration FDA grants accelerated approval to pembrolizumab for first tissue site agnostic indication Available at https www fda gov drugs informationondrugs approveddrugs ucm htm Accessed","year":"2017","journal-title":"Food Drug October"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/01.ju.0000087822.71739.9a","article-title":"Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors","volume":"170","author":"Sheinfeld","year":"2003","journal-title":"J Urol"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/annonc\/mdu375","article-title":"One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group","volume":"25","author":"Tandstad","year":"2014","journal-title":"Ann Oncol"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdm062","article-title":"Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)","volume":"18","author":"Culine","year":"2007","journal-title":"Ann Oncol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2003.07.169","article-title":"Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial","volume":"21","author":"Albers","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.0.CO;2-A","article-title":"Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis","volume":"83","author":"Heidenreich","year":"1998","journal-title":"Cancer"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.eururo.2006.05.011","article-title":"Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor","volume":"50","author":"De Giorgi","year":"2006","journal-title":"Eur Urol"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0959-8049(00)00442-1","article-title":"Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse","volume":"37","author":"Alexandre","year":"2001","journal-title":"Eur J Cancer"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2013.53.5831","article-title":"Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort","volume":"32","author":"Daugaard","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00005392-199501000-00030","article-title":"The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989)","volume":"153","author":"Donohue","year":"1995","journal-title":"J Urol"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mds460","article-title":"Testicular cancer in Europe and the USA: survival still rising among older patients","volume":"24","author":"Verhoeven","year":"2013","journal-title":"Ann Oncol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.11229","article-title":"Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients","volume":"97","author":"Ragni","year":"2003","journal-title":"Cancer"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.juro.2006.06.012","article-title":"Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?","volume":"176","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"ref2731","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000351812","article-title":"Management of brain metastases from germ cell tumors: a single center experience","volume":"85","author":"Boyle","year":"2013","journal-title":"Oncology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1677\/ERC-09-0254","article-title":"Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype","volume":"17","author":"Greene","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5489\/cuaj.3024","article-title":"Do retroperitoneal extragonadal germ cell tumours exist?","volume":"9","author":"Punjani","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"ref1491","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref2751","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1008388328809","article-title":"First-line high-dose chemotherapy +\/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases","volume":"11","author":"Kollmannsberger","year":"2000","journal-title":"Ann Oncol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2001.19.7.2020","article-title":"Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse","volume":"19","author":"Rabbani","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00005392-200102000-00022","article-title":"Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer","volume":"165","author":"B\u00f6hlen","year":"2001","journal-title":"J Urol"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.urology.2011.02.002","article-title":"Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy","volume":"78","author":"Kundu","year":"2011","journal-title":"Urology"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1442-2042.2002.00520.x","article-title":"Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy","volume":"9","author":"Nonomura","year":"2002","journal-title":"Int J Urol"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2005.07.132","article-title":"Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome","volume":"23","author":"Stephenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/0284186X.2018.1449249","article-title":"Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life","volume":"57","author":"Schmidt","year":"2018","journal-title":"Acta Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1387\/ijdb.130031nv","article-title":"Classification, epidemiology and therapies for testicular germ cell tumours","volume":"57","author":"Vasdev","year":"2013","journal-title":"Int J Dev Biol"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2009.23.0755","article-title":"Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery","volume":"28","author":"Kollmannsberger","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1148\/rg.275065172","article-title":"US MR imaging correlation in pathologic conditions of the scrotum","volume":"27","author":"Kim","year":"2007","journal-title":"Radiographics"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/era.10.219","article-title":"Serum tumor markers and their utilization in the management of germ-cell tumors in adult males","volume":"11","author":"Salem","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/COC.0b013e31829e19e0","article-title":"Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"38","author":"Mulherin","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2017.77.0735","article-title":"Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study","volume":"36","author":"Kerns","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/annonc\/mdn170","article-title":"[18F]-FDG-PET in clinical stage I\/II non-seminomatous germ cell tumours: results of the German multicentre trial","volume":"19","author":"de Wit","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/17\/12\/article-p1529.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T15:57:09Z","timestamp":1596815829000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/17\/12\/article-p1529.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":266,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2019.0058","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}